Shandong Xinhua Pharma Secures FDA Approval for New Drug
Company Announcements

Shandong Xinhua Pharma Secures FDA Approval for New Drug

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.

Shandong Xinhua Pharmaceutical Company Limited has announced that its abbreviated new drug application (ANDA) for sevelamer carbonate tablets has received approval from the U.S. Food and Drug Administration (FDA). This development positions the company to enter the market with a prescription drug designed to control hyperphosphatemia in adults with chronic kidney disease undergoing dialysis. The tablets, originally developed by Sanofi Genzyme, are already used in over 40 countries, enhancing their market potential.

For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharmaceutical Announces December EGM
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharma Secures Key Drug Approval
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua’s Generic Drug Receives Key Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App